Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.joms.2012.03.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature.
Ann Transl Med
December 2020
Division of Gynecologic Oncology, Gemelli-Molise, Università Cattolica del Sacro Cuore, Campobasso, Italia.
In patients undergoing debulking surgery for ovarian cancer (OC), bevacizumab-combined chemotherapy has been reported to be associated with an increased incidence of adverse events (AEs). Reports in the literature have noted the overall morbidity of bevacizumab to be between 3.7% and 9%.
View Article and Find Full Text PDFIntraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report.
J Med Case Rep
July 2012
Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey.
Introduction: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It is widely used in the treatment of metastatic colorectal cancer. It has some specific side effects including severe bleeding, wound healing problems, gastrointestinal perforation, proteinuria and hypertension.
View Article and Find Full Text PDFUnusual bevacizumab-related complication of an oral infection.
J Oral Maxillofac Surg
January 2013
Department of Oral and Maxillofacial Surgery, Saint-Luc University Hospital and Cancer Center, Université Catholique de Louvain, Brussels, Belgium.
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment.
Anticancer Res
May 2009
Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Rd, Taipei 10002, Taiwan, R.O.C.
Bowel perforation is a rare but life-threatening complication of bevacizumab, a new anticancer treatment. Patients with bowel perforation usually present with acute abdominal symptoms. Here a case history is presented to highlight a pancreatic cancer patient on bevacizumab chemotherapy who developed empyema as the first manifestation of gastric perforation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!